Miyata Yasuyoshi, Matsuo Tomohiro, Araki Kyohei, Nakamura Yuichiro, Sagara Yuji, Ohba Kojiro, Sakai Hideki
Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 852-8501 Nagasaki, Japan.
Medicines (Basel). 2018 Aug 10;5(3):87. doi: 10.3390/medicines5030087.
Green tea and green tea polyphenols (GTPs) are reported to inhibit carcinogenesis and malignant behavior in several diseases. Various in vivo and in vitro studies have shown that GTPs suppress the incidence and development of bladder cancer. However, at present, opinions concerning the anticancer effects and preventive role of green tea are conflicting. In addition, the detailed molecular mechanisms underlying the anticancer effects of green tea in bladder cancer remain unclear, as these effects are regulated by several cancer-related factors. A detailed understanding of the pathological roles and regulatory mechanisms at the molecular level is necessary for advancing treatment strategies based on green tea consumption for patients with bladder cancer. In this review, we discuss the anticancer effects of GTPs on the basis of data presented in in vitro studies in bladder cancer cell lines and in vivo studies using animal models, as well as new treatment strategies for patients with bladder cancer, based on green tea consumption. Finally, on the basis of the accumulated data and the main findings, we discuss the potential usefulness of green tea as an antibladder cancer agent and the future direction of green tea-based treatment strategies for these patients.
据报道，绿茶及绿茶多酚（GTPs）可抑制多种疾病中的致癌作用及恶性行为。多项体内和体外研究表明，GTPs可抑制膀胱癌的发生和发展。然而，目前关于绿茶抗癌作用及预防作用的观点相互矛盾。此外，绿茶在膀胱癌中的抗癌作用背后的详细分子机制仍不清楚，因为这些作用受多种癌症相关因素调控。深入了解分子水平的病理作用和调控机制对于推进基于饮用绿茶的膀胱癌患者治疗策略至关重要。在本综述中，我们根据在膀胱癌细胞系的体外研究及使用动物模型的体内研究中呈现的数据，讨论GTPs的抗癌作用，以及基于饮用绿茶的膀胱癌患者新治疗策略。最后，基于积累的数据和主要研究结果，我们讨论绿茶作为抗膀胱癌药物的潜在效用以及针对这些患者的基于绿茶的治疗策略的未来方向。
